BRD4 and neoplasm: In both BRD4 amplified models, over the 25-day course of drug administration, at 5 and 10 mg/kg QD, AZD5153 led to tumor stasis, with 100% tumor growth inhibition (TGI) in OV0857F and 98% TGI in HOXF062 respectively (Fig 6C and 6D).